ArticleScientific reports2025
A visualized machine learning model using noninvasive parameters to differentiate men with and without prostatic carcinoma before biopsy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting Prostate Cancer Risk and Its Associated Factors Using Machine Learning Techniques: A Retrospective Study.Health science reports · 2026Article
- Multiple programmed cell death patterns predict the prognosis and therapeutic sensitivity in head and neck squamous cell carcinoma.Discover oncology · 2026Article
- Association between amide proton transfer-weighted imaging biomarkers and Gleason score in prostate cancer: a study on differential diagnosis from benign prostatic hyperplasia.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aimed to create a visualized extreme gradient boosting (XGBOOST) model to distinguish prostatic carcinoma (PCA) from non-PCA using noninvasive prebiopsy parameters before biopsy. This was a cross-sectional study of 310 Chinese men who underwent prostate biopsy and were divided into PCA (n = 126) and non-PCA (n = 184) groups. The non-PCA patients were diagnosed with benign prostatic hyperplasia (BPH) based on biopsy results. The XGBOOST model was used to analyze 15 noninvasive prebiopsy parameters. The model performance was assessed by the area under the receiver operating characteristic curve (AUC) and compared with four other machine learning models (decision tree learning, lasso, neural network (NNET), and support vector machine (SVM)) and a logistic model. The logistic model identified serum thymidine kinase 1 (STK1p), total prostate-specific antigen (TPSA), and age as key prognostic factors. In the Lasso procedure, free prostate-specific antigen (FPSA) and free-to-total prostate-specific antigen (FTPSA) were also added to machine learning models. The XGBOOST model achieved an AUC of 0.965, which was significantly greater than those of other models (AUC = 0.708-0.817) and the logistic model (AUC = 0.813) (P < 0.001). The 49 decision trees generated by the XGBOOST model were visualized to aid in decision making. This study successfully developed a visualized XGBOOST model with high accuracy in differentiating PCA from non-PCA using eight noninvasive predictors. This model could aid in the precise selection of high-risk PCA patients for biopsy, potentially minimizing unnecessary procedures and their associated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.